


January 2014

Corporate Profile

Global Green, Inc. plans to manufacture, market and sell the U.S. patented, exclusively licensed vaccine known as the Salmogenics Vaccine, "Salmogenics™", to combat Salmonella bacteria in poultry and eggs. The vaccine is currently in the final stage of the USDA approval process.

The vaccine is unique in that it is injected directly into the egg, before the chick is hatched, improving the immune system, health and welfare of the chicken, and providing a healthier source of protein for humans.



Salmogenics™ was developed by Nutritional Health Institute Laboratories, LLC (a research affiliate and our majority shareholder).



Domestic Market Opportunity

- Salmonella costs \$3 billion a year in U.S. ¹
- Approximately 1.3 billion humans contract Salmonella annually worldwide, with 2-3 million resulting in death ²
- 1.2 million humans in the U.S. contract Salmonella annually ³
- Approximately 9 billion broiler chickens were produced ⁴
- Almost 37 billion pounds of chicken products will be marketed, measured on ready-to-cook basis ⁵
- Consumer expenditures for chickens total \$70 billion ⁶
- 9.6 billion chickens would benefit from Salmogenics
- The Centers for Disease Control reports that the incidence of Salmonella was the least improved of all foodborne pathogens in terms of achieving national health objective targets for Healthy People 2010.

Sources:

(1) World Health Organization, 2005, (2) Centers for Disease Control, (3) (4) (5) (6) National Chicken Council, 2011

Trial Studies Indicate Use of Salmogenics May Improve Performance of Broilers

- Continuing internal field trial studies show that the use of Salmogenics may increase the performance of broilers, resulting in a healthier protein source and leading to increased profit for the poultry grower. Comparing the experimental or vaccinated broilers over the controls, the studies indicated:
- Improved broiler performance included an average of a .126 pound weight gain, with each bird weighing an average of 5.73 pounds
- Feed conversion improvement of 0.039%
- Mean mortality dropped to 1.406% as compared to the 3.281%, representing a 57% improvement
- Further studies will be conducted to determine the levels of enhancement that Salmogenics could produce in injected broilers.

The Global Green Vaccine Advantage is Significant

Salmogenics Vaccine

- **Fast delivery**
- **Uniform delivery system**
- **Earlier immunity from salmonella**
- **Reduced stress on chickens**
- **Reduced labor costs for inoculation**
- **Improved productivity of chickens**
- **Potential future products for other animals**

September 4, 2013

Global Green, Inc. announced the signing of an agreement with Merial Ltd., the Animal Health Division of Sanofi, to conduct an internal evaluation of Global Green's patented Salmogenics vaccine technology. At the conclusion of the evaluation, Merial has the first option to enter into a license agreement with Global Green for the manufacture, distribution, and sale of the vaccine.

[Read full press release](#)